Teclistamab Myeloma Study: Improved Tolerance & Responses

Summary of the Study on Teclistamab in ⁣Newly Diagnosed Multiple Myeloma (NDMM)

This study investigated the safety and effectiveness of teclistamab, a novel ⁢bispecific antibody targeting BCMA, when combined with daratumumab (DARA)-based regimens in 50 patients with transplant-eligible (TE) NDMM.This is the first trial to assess teclistamab as a front-line treatment ⁢with a steroid-sparing approach.

Key Details:

* Participants: ‍ 50 patients (49 treated) aged 30-68 (average 58).
* Study Arms: Patients were divided into three arms (A, A1, and B) with varying teclistamab dosages⁢ and schedules, all combined with daratumumab⁢ and lenalidomide. Some arms also included bortezomib. (See image for specific ⁤details of each arm).
* Treatment: All patients received daratumumab⁢ and⁢ lenalidomide. teclistamab dosage varied by arm, administered subcutaneously, orally, or intravenously. Dexamethasone was also used, with varying schedules.
* Outcomes:

⁢⁤ ⁣ * Stem Cell Collection: 47 patients proceeded to‍ stem ⁤cell collection, with 46 successfully mobilized.
* Discontinuations: 8 ⁣patients stopped lenalidomide, 2 ‍stopped ⁢bortezomib, and 1 stopped ⁣teclistamab, primarily due⁣ to treatment-related toxicities.
* Teclistamab Background: Approved in 2022 ⁤for⁣ patients with relapsed/refractory MM after failing⁤ 4 prior therapies (proteasome⁤ inhibitor, immunomodulatory agent, anti-CD38 monoclonal antibody).

In essence, the study ⁤aimed to see how well teclistamab works when given early in the treatment of multiple myeloma, in combination with standard therapies,⁣ and to minimize the use of steroids.